Limited Edition Golden Llama is here! Check out how you can get one.
Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free!
Offering SPR-BLI Services - Proteins provided for free!
Thank you for choosing ACROBiosystems. Would you rate our product and service?
Thank you for choosing ACROBiosystems. Would you rate our product and service?
Here come GMP Grade Cytokines!Free Sample is available!
Here come GMP Grade Cytokines!Free Sample is available!
This protein carries a polyhistidine tag at the C-terminus.
This protein contains a furin convertase cleavage site, 737-RKRR-740, and will be partially processed into N (α chain) and C-terminal fragment (partial β chain) with calculated MW of 81.0 kDa and 23.8 kDa respectively. The protein migrates as 35-45 kDa (partial β chain), 110-120 kDa (α chain) and 130 kDa (α chain & partial β chain) under reducing (R) condition (SDS-PAGE) due to glycosylation.
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Human IGF-I R, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.
The purity of Human IGF-I R, His Tag (Cat. No. IGR-H5229) is more than 90% and the molecular weight of this protein is around 252-308 kDa verified by SEC-MALS.
Immobilized Human IGF-I R, His Tag (Cat. No. IGR-H5229) at 5 μg/mL (100 μL/well) can bind Human IGF-I, Fc Tag with a linear range of 0.01-0.625 μg/mL (QC tested).
Human IGF-I R, His Tag (Cat. No. IGR-H5229) immobilized on CM5 Chip can bind Biotinylated Human IGF-I, His,Avitag (Cat. No.IG1-H82Q6) with an affinity constant of 68 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).
Human IGF-I R, His Tag (Cat. No. IGR-H5229) captured on CM5 chip via anti-His antibody can bind Human IGF-I, Fc Tag with an affinity constant of 0.189 μM as determined in a SPR assay (Biacore 8K) (Routinely tested).
Human IGF-I R, His Tag (Cat. No. IGR-H5229) immobilized on CM5 Chip can bind Biotinylated Human IGF-II, His,Avitag with an affinity constant of 51.2 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).
ACROBiosystemsは、二重特異性抗体の治療薬への臨床開発を加速するために、高い生物活性を持つ均一なCD3δ/CD3εおよびCD3γ/CD3εタンパク質のシリーズを開発しました。
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox は、即使用可能のオルガノイド、オルガノイド分化ツールキット、創薬プロジェクトの進行を加速する、さまざまなサービスを含むオルガノイドソリューションのことです。
IL-15、IL-7、IL-21など、高品質のGMP準拠サイトカイン製品を提供しており、免疫細胞治療薬の臨床研究をサポートし、医薬品規制当局の承認を加速できます。
注目されている50以上のCAR-Tターゲットがあり、CARの発現の検出のために設計された抗原タンパク質をフローサイトメトリーで検証し、CARの発現が高い特異性で検出できます。ロット間の一貫性が保証されています。また、PE / FITC標識タンパク質を利用することで、ワンステップ染色でCARの発現を高い特異性でバックグラウンドなしに検出できます。
CD20、Claudin18.2、CD133、GPRC5D、CCR5、CCR8などの安定で高活性な全長型膜貫通タンパク質は、免疫学、ELISA、SPR、BLI、細胞実験、CAR陽性率検出に利用できます。VLP、界面活性剤、ナノディスクなどのテクニカルプラットフォームによって複数回膜貫通タンパク質の医薬品創薬を促進できます。
GMP準拠サイトカイン、高品質の細胞活性化/増幅試薬、遺伝子改変試薬/酵素、CAR検出試薬などの製品を提供し、細胞、遺伝子治療用に全体的なソリューションを提供し、創薬から臨床研究までのすべての段階をサポートします。
これまでに知られている免疫チェックポイント分子をほぼ製品化しており、様々なタグの製品群を提供できます。天然高分子の構造はMALSによって、生物活性はELISA/SPR/BLI/FACSなどによって検証済みです。またBiotin/FITCなどの標識も選択でき、抗体のハイスループットスクリーニングに利用できます。
弊社ACROBiosystemsはADC医薬品の開発のサポートに取り組み、注目されている様々なターゲットのために、異なる種類とタグの製品が開発され、高い純度と親和性が特長です。免疫、抗体スクリーン、SPR、細胞活性検査などの実験に利用できます。Protocolも無償で提供いたします。
すべての分子のFc受容体タンパク質だけでなく、一般的な変異体やビオチン標識タイプも含まれております。お客様のモノクローナル抗体の開発をサポートします。
インターロイキン、成長因子、ケモカイン、TNF など、様々なサイトカインターゲットの自然なコンフォメーションを確保するために HEK293 によって発現されます。SDS-PAGE/HPLC/SEC-MALS によって高純度は確認され、高い生物活性は ELISA/SPR/BLI によって確認されています。
AneuroはACROBiosystemsが神経科学研究のために設計した製品群のブランドです。神経科学研究を推進するための治療・診断用研究タンパク質、PFF、組み換え神経因子など、高品質の重要なタンパク質を提供しております。
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Mecasermin (Astellas/OrphanPacific) | Approved | Astellas Pharma Inc | Somazon | Japan | Growth hormone deficiency; Diabetes Mellitus, Lipoatrophic; Dwarfism | null | 1994-10-05 | Diabetes Mellitus, Lipoatrophic; Heart Failure; Myocardial Infarction; Multiple Sclerosis; HIV-Associated Lipodystrophy Syndrome; Dwarfism; Growth hormone deficiency | Details | |
Mecasermin (Ipsen) | FK-780; IGF-1; MKN-031; rhIGF-I (Ipsen) | Approved | Genentech Inc | Increlex | United States | Failure to Thrive | Ipsen Inc | 2005-08-30 | Failure to Thrive; Autism Spectrum Disorder; Phelan-McDermid syndrome; X-Linked Combined Immunodeficiency Diseases; Growth Disorders; Laron Syndrome | Details |
Brigatinib | AP-26113 | Approved | Ariad Pharmaceuticals Inc | Alunbrig, ALUNBRIG | United States | Carcinoma, Non-Small-Cell Lung | Takeda Pharmaceuticals USA Inc | 2017-04-28 | Solid tumours; Ependymoma; Carcinoma; Neoplasms; Neurofibromatosis 2; Myofibroma; Lymphoma, Large-Cell, Anaplastic; Granuloma, Plasma Cell; Lung Neoplasms; Brain metastases; Carcinoma, Non-Small-Cell Lung; Sarcoma, Kaposi; Neurilemmoma; Neuroma, Acoustic; Meningioma | Details |
IGF-1 (Biogen/Pharmacia & Upjohn) | Approved | Biogen Inc, Pharmacia & Upjohn | Igef | Sweden | Dwarfism | null | 1994-01-01 | Dwarfism | Details | |
Ceritinib | LDK-378; NVP-LDK378; NVP-LDK378-NX | Approved | Novartis Pharma Ag | 赞可达, Zykadia | EU | Carcinoma, Non-Small-Cell Lung | Novartis Europharm Ltd | 2014-04-29 | Hepatic Insufficiency; Adenocarcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung; Brain metastases; Esophageal adenocarcinoma; Granuloma, Plasma Cell; Lymphoma, Large-Cell, Anaplastic; Thyroid Neoplasms; Hematologic Neoplasms; Colorectal Neoplasms; Cholangiocarcinoma; Neoplasms; Pancreatic Neoplasms; Glioblastoma; Thyroid Carcinoma, Anaplastic; Stomach Neoplasms | Details |
Teprotumumab | R-1507; RG-1507; RO-4858696; HZN-001; RV-001(River Vision) | Approved | Genmab A/S, F. Hoffmann-La Roche Ltd | Tepezza | United States | Graves Ophthalmopathy | Horizon Therapeutics Ireland | 2020-01-21 | Neoplasms; Graves Ophthalmopathy; Breast Neoplasms; Sarcoma; Diabetic macular oedema; Scleroderma, Diffuse; Carcinoma, Non-Small-Cell Lung | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Veligrotug | ZB-001; VRDN-001; AVE-1642 | Phase 3 Clinical | Viridian Therapeutics Inc | Solid tumours; Graves Ophthalmopathy; Multiple Myeloma; Breast Neoplasms | Details |
VRDN-003 | VRDN-003 | Phase 3 Clinical | Viridian Therapeutics Inc | Graves Ophthalmopathy | Details |
Ganitumab | AMG-479 | Phase 3 Clinical | Amgen Inc | Breast Neoplasms; Neuroectodermal Tumors, Primitive, Peripheral; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Lymphoma; Lung Neoplasms; Rhabdomyosarcoma, Alveolar; Colorectal Neoplasms; Neuroectodermal Tumors, Primitive; Sarcoma; Prostatic Neoplasms; Solid tumours; Sarcoma, Ewing; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Carcinoid Tumor; Rhabdomyosarcoma, Embryonal; Ovarian Neoplasms; Intestinal Neoplasms; Bone metastases; Rhabdomyosarcoma | Details |
Linsitinib | OSI-906; ASP-7487; OSI-906AA | Phase 3 Clinical | Astellas Pharma Inc, National Cancer Institute | Multiple Myeloma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Paraganglioma; Mouth Neoplasms; Lip Neoplasms; Eye Diseases; Orbital Diseases; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Exophthalmos; Carcinoma, Basosquamous; Prostatic Neoplasms; Sarcoma, Ewing; Breast Neoplasms; Adrenocortical Carcinoma; Liver Neoplasms; Graves Ophthalmopathy; Endocrine System Diseases; Hormone-Resistant Prostate Neoplasms; Skin Neoplasms; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Neoplasms; Hashimoto Disease; Head and Neck Neoplasms; Ovarian Neoplasms; Chondrosarcoma; Thyroid Diseases; Solid tumours; Carney Complex | Details |
FPI-1434 | [225Ac]-FPI-1434; FPX-01 | Phase 2 Clinical | Fusion Pharma | Solid tumours; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Neoplasms; Adrenocortical Carcinoma; Uveal melanoma; Breast Neoplasms; Endometrial Neoplasms; Uterine Cervical Neoplasms | Details |
Dalotuzumab | h7C-10; MK-0646; F-50-035 | Phase 2 Clinical | Pierre Fabre Group | Solid tumours; Rectal Neoplasms; Pancreatic Neoplasms; Neoplasms; Multiple Myeloma; Neuroendocrine Tumors; Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung | Details |
CT-102 | CT-102 | Phase 2 Clinical | Hangzhou Tianlong Pharmaceutical Co Ltd, Institute Of Radiation And Radiation Medicine, Chinese Academy Of Military Medical Sciences | Liver Neoplasms; Carcinoma, Hepatocellular | Details |
Mecasermin Rinfabate | rhIGF-I/rhIGFBP-3; TAK-607; OHB-607; IGF-I/IGFBP-3; SHP-607; HGT-ROP-001 | Phase 2 Clinical | Insmed | Noonan Syndrome; Failure to Thrive; Cerebral Intraventricular Hemorrhage; Lung Diseases; Myotonic Dystrophy; Bronchopulmonary Dysplasia; Retinopathy of Prematurity; Laron Syndrome | Details |
Insulin growth factor receptor type 1 antisense therapy (Imvax) | IGV-001 | Phase 2 Clinical | Thomas Jefferson University | Glioblastoma | Details |
MHB018A | MHB 018A; MHB-018A | Phase 2 Clinical | Minghui Pharmaceutical (Hangzhou) Co Ltd | Graves Ophthalmopathy | Details |
PHP-1003 | PHP-1003; PHP1003 | Phase 2 Clinical | Suzhou Pulekang Pharmaceutical Technology Co Ltd | Graves Ophthalmopathy | Details |
Lonigutamab | VB-421 | Phase 2 Clinical | Pierre Fabre Group | Graves Ophthalmopathy | Details |
Cixutumumab | A-12; IMC-A12; LY-3012217; NSC-742460 | Phase 2 Clinical | Eli Lilly And Company | Chondrosarcoma, Extraskeletal Myxoid; Pinealoma; Brain Stem Neoplasms; Gliosarcoma; Breast Neoplasms; Gastrinoma; Medullary thyroid cancer (MTC); Lymphoma, Mantle-Cell; Neuroblastoma; Adenocarcinoma, Bronchiolo-Alveolar; Osteosarcoma; Retinoblastoma; Neurofibrosarcoma; Sarcoma; Sarcoma, Ewing; Prostatic Neoplasms; Glucagonoma; Mesothelioma; Glioma; Adenocarcinoma; Melanoma; Paraganglioma; Carcinoma, Non-Small-Cell Lung; Breast Neoplasms, Male; Carcinoma, Hepatocellular; Neuroectodermal Tumors, Primitive, Peripheral; Carcinoma, Neuroendocrine; Neuroendocrine Tumors; Esophageal Squamous Cell Carcinoma; Hemangiopericytoma; Esophageal adenocarcinoma; Sarcoma, Alveolar Soft Part; Lung Neoplasms; Rhabdomyosarcoma, Alveolar; Metastatic breast cancer; Colorectal Neoplasms; Hepatoblastoma; Stomach Neoplasms; Mesenchymoma; Rectal Neoplasms; Carcinoma, Merkel Cell; Esophageal Neoplasms; Insulinoma; Squamous Cell Carcinoma of Head and Neck; Rhabdomyosarcoma, Embryonal; Carcinoma; Desmoplastic Small Round Cell Tumor; Hema | Details |
Picropodophyllin | PPP; AXL-1717; NSC-36407 | Phase 2 Clinical | Axelar Ab | Astrocytoma; Carcinoma, Non-Small-Cell Lung | Details |
NNC0268-0965 | NNC0268-0965 | Phase 1 Clinical | Novo Nordisk A/S | Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 | Details |
IGF-1 receptor oligodeoxynucleotide-based immunotherapy (Thomas Jefferson University) | Phase 1 Clinical | Sidney Kimmel Cancer Center | Glioma | Details | |
Insulin-Like Growth Factor 1 (Wright State Physicians) | Phase 1 Clinical | Wright State Physicians | Nasolabial fold wrinkles; Healthy Aging; Burns; Sunburn | Details | |
SAR-446159 | ABL-301; SAR-446159 | Phase 1 Clinical | Abl Bio Inc | Parkinson Disease | Details |
VRDN-002 | VRDN-002 | Phase 1 Clinical | Viridian Therapeutics Inc | Graves Ophthalmopathy | Details |
LX-101 (Lirum Therapeutics) | 765IGF-MTX; IGF/MTX | Phase 1 Clinical | Lirum Therapeutics Inc | Head and Neck Neoplasms; Anemia, Refractory, with Excess of Blasts; Neoplasms; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Graves Ophthalmopathy; Brain Neoplasms; Breast Neoplasms; Genital Neoplasms, Female; Urogenital Neoplasms; Gastrointestinal Neoplasms; Melanoma | Details |
ZB-011 | ZB-011; ZB011 | Phase 1 Clinical | Viridian Therapeutics Inc | Graves Ophthalmopathy | Details |
Teprotumumab biosimilar(Boxiao Bio-pharma) | Phase 1 Clinical | Zhejiang Boxiao Bio-pharmaceutical Co Ltd | Graves Ophthalmopathy | Details | |
124I-CPD-1023-figitumumab | 124I-CPD-1028; 125I-CPD-1028; CPD-1028-[124I]; CPD-1028-[125I]; FPX-1028 | Phase 1 Clinical | Fusion Pharma | Neoplasms | Details |
ALTSuLIN | Clinical | Diabetes Mellitus, Type 1; Laron Syndrome | Details |
This web search service is supported by Google Inc.